Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population

[1]  C. Perno,et al.  Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. , 2011, Antiviral research.

[2]  A. M. Ismail,et al.  Antiviral Resistance Mutations and Genotype-Associated Amino Acid Substitutions in Treatment-Naïve Hepatitis B Virus-Infected Individuals from the Indian Subcontinent , 2011, Intervirology.

[3]  S. Chakrabarti,et al.  Variations in the functional domain of basal core promoter of hepatitis B virus among Eastern Indian patients with prevalence of genotypes A, C, and D among the same ethnic population , 2011, Journal of medical virology.

[4]  H. Zhuang,et al.  Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. , 2010, Antiviral research.

[5]  S. Chakrabarti,et al.  Subgenotypes of hepatitis B virus genotype D (D1, D2, D3 and D5) in India: differential pattern of mutations, liver injury and occult HBV infection , 2009, Journal of viral hepatitis.

[6]  G. Magiorkinis,et al.  Quantitative Detection of the M204V Hepatitis B Virus Minor Variants by Amplification Refractory Mutation System Real-Time PCR Combined with Molecular Beacon Technology , 2009, Journal of Clinical Microbiology.

[7]  S. Bhattacharya,et al.  Genetic Characterization of Hepatitis B Virus in Peripheral Blood Leukocytes: Evidence for Selection and Compartmentalization of Viral Variants with the Immune Escape G145R Mutation , 2009, Journal of Virology.

[8]  F. Ceccherini‐Silberstein,et al.  The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. , 2009, Journal of hepatology.

[9]  T. Baumert,et al.  Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. , 2009, World journal of gastroenterology.

[10]  Alessandro Bruselles,et al.  Use of Massively Parallel Ultradeep Pyrosequencing To Characterize the Genetic Diversity of Hepatitis B Virus in Drug-Resistant and Drug-Naive Patients and To Detect Minor Variants in Reverse Transcriptase and Hepatitis B S Antigen , 2008, Journal of Virology.

[11]  K. Borroto-Esoda,et al.  Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. , 2007, Journal of hepatology.

[12]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[13]  N. Warner,et al.  The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro , 2007, Antimicrobial Agents and Chemotherapy.

[14]  S. Locarnini,et al.  Antiviral drug resistance: clinical consequences and molecular aspects. , 2006, Seminars in liver disease.

[15]  S. Locarnini,et al.  Cellular and virological mechanisms of HBV drug resistance. , 2006, Journal of hepatology.

[16]  S. Locarnini,et al.  Hepatitis B virus mutations associated with antiviral therapy , 2006, Journal of medical virology.

[17]  P. Coursaget,et al.  Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes , 2004, Intervirology.

[18]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.